Background
==========

Lenalidomide (LEN) is particularly effective in patients with myelodysplastic syndromes (MDS) and the del\[5q\] cytogenetic abnormality \[[@B1]-[@B3]\]. In MDS-003, the phase II registration trial of 148 lower-risk MDS patients with del\[5q\] with or without other karyotypic abnormalities, 67% achieved transfusion independence with a complete and partial cytogenetic response rate of 45% and 28%, respectively \[[@B2]\]. There was no significant association between karyotypic complexity and the frequency of a cytogenetic response. LEN also has activity in a proportion of MDS without del\[5q\] \[[@B4]\] and \[[@B5]\]. Transfusion-dependent MDS patients low- or Int-1 by the International Prognostic Scoring System (IPSS) without del\[5q\] achieved a 43% overall rate of hematologic improvement \[[@B4]\]. However, there were no significant differences in the rate of transfusion independence according to age, sex, FAB type, IPSS category, cytogenetic pattern, or early cytopenias. In higher risk (IPSS; Int-2, high) MDS patients with del\[5q\] with or without other karyotypic abnormalities, 27% achieved complete remission (CR), including 67% of patients with isolated del\[5q\], vs. 1/1 and 0/27 patients with one or more than one additional chromosomal abnormalities, respectively (*P*\< .001) \[[@B3]\]. Recently, high-dose LEN therapy resulted in a 14% CR/partial response (PR) rate in AML patients with del\[5q\] \[[@B6]\], and a 30% CR/complete remission without complete recovery of all blood counts (CRi) rate in older AML patients without del\[5q\] \[[@B5]\]. To date, the presence of del\[5q\] with or without additional chromosomal abnormalities detected by metaphase cytogenetics (MC) remains the best prognostic factor for response to LEN. As patients without del\[5q\] can also show responses to LEN, identification of additional markers of response/resistance is of utmost importance. Clinically, cytogenetic abnormalities including cryptic deletions of 5q, along with certain other mutations, may constitute additional lesions predictive of response. For instance, the presence of *TP53*mutations has been shown to be associated with poor prognosis in azacitidine-treated MDS patients \[[@B7]\], and in LEN-treated MDS or AML patients with del\[5q\] \[[@B8],[@B9]\].

The diagnostic yield of MC can be enhanced by application of fluorescence in situ hybridization (FISH) for targeted detection of chromosomal lesions including del\[5q\], as this technique is considered to be more sensitive and allow for detection of smaller clones \[[@B10]\]. Similarly, single nucleotide polymorphism array (SNP-A)-based karyotyping, due to its superb resolution, may allow for detection of previously cryptic unbalanced chromosomal defects \[[@B10]\] and \[[@B11]\]. Both techniques can be performed on interphase cells, and thereby do not require cell division.

In addition to mostly unbalanced cytogenetic defects, mutations of a number of genes, including *TET2*\[[@B12],[@B13]\], *UTX*\[[@B14]\], *CBL*\[[@B15]\], *EZH2*\[[@B16]-[@B18]\], *ASXL1*\[[@B19]-[@B21]\], *TP53*\[[@B7],[@B22],[@B23]\], *RAS*\[[@B24],[@B25]\], *IDH1/2*\[[@B26]\], and *DNMT3A*\[[@B27]\] have been implicated in the pathogenesis of MDS and may also modulate clinical features including responsiveness to LEN.

We examined a cohort of patients without del\[5q\] treated with LEN and explored the relationship between molecular features and clinical response to LEN.

Methods
=======

Patients
--------

Bone marrow (BM) and/or peripheral blood (PB) were collected from 755 patients with myeloid malignancies seen at Cleveland Clinic (CC) and H. Lee Moffitt Cancer Center between 2002 and 2010. First, a cohort of 122 patients, who were examined with all 3 cytogenetic methods (MC, FISH and SNP-A) on the same sample, was collected. Next, data from 42 patients with MDS (31; RA, 5; RARS, 13; RCMD, 1; RAEB-1, 4; RAEB-2, 7; MDS-U, 1), myeloproliferative neoplasms (MPN) (PMF, 2), MDS/MPN overlap syndrome (7; CMML-1, 2; CMML-2, 2; MDS/MPN-U, 3), or 2 secondary acute myeloid leukemia (sAML) without del\[5q\], who received LEN for at least 8 weeks, were collected retrospectively. The schedule and dosage of lenalidomide was primarily 10 mg/day (5 mg/day in a few cases) for 1-21 days, with a 28-day cycle. All bone marrow biopsies were reviewed and diagnoses confirmed at Cleveland Clinic and H. Lee Moffitt Cancer Center. Response to LEN was defined by the modified International Working Group (IWG) response criteria (2006) \[[@B28]\]. Informed consent for sample and clinical information collection was obtained according to protocols approved by the Cleveland Clinic or the H. Lee Moffitt Cancer Center IRBs.

Cytogenetic analysis
--------------------

Cytogenetic analysis was performed on marrow aspirates and/or peripheral blood, in cases where bone marrow samples could not be obtained, according to standard methods (Figure [1](#F1){ref-type="fig"}). 20 metaphase spreads were examined per patient, if available. Chromosome preparations were G-banded using trypsin and Giemsa (GTG) and karyotypes were described according to ISCN \[[@B29]\].

![**Detection of chromosome 5 abnormalities by different cytogenetic techniques**. Examples of normal chromosome 5 (A) and deleted chromosome 5 (B) are presented. The deleted lesion is denoted by a shorter chromosome in MC (top left panel, blue arrow), a single red signal in FISH (top right panel) and segmental copy number loss in the SNP-A karyotype (bottom panel).](1756-8722-5-4-1){#F1}

Fluorescence in situ hybridization
----------------------------------

FISH analysis was performed on cell pellets from unstimulated cytogenetic cultures. Thresholds for interpretation as a positive result were established for each probe at 3 standard deviations above the mean of 20 normal bone marrow samples. In 27 cases, FISH analysis was performed at an outside reference laboratory (Mayo Clinic) using the following dual color probe sets: 5p15.2 (normal range; 0-4%)/EGR1 (5q31) (0-6%), CEP7 (0-5%)/7q31 (0-7%), CEP8 (0-2%)/MYC (8q24) (0-2%) and 20q12 (0-5%)/20qter (0-5%). In 95 cases, FISH was performed at CC using three dual color probe sets (Abbott Molecular, Abbott Park, IL). The first probe set consisted of D5S23 and D5S721 (5p15.2) labeled in Spectrum Green (0-6%) and EGR1 (5q31) labeled in Spectrum Orange (0-6%). The second probe set consisted of the chromosome 7 centromere labeled in Spectrum Green (0-5%) and D7S486 (7q31) labeled in Spectrum Orange (0-7%). The third probe set consisted of the chromosome 8 centromere labeled in Spectrum Green (0-8%) and D20S108 (20q12) labeled in Spectrum Orange (0-4%).

DNA extraction
--------------

DNA was extracted from whole bone marrow using the ArchivePure Kit (5Prime, Gaithersburg, MD) per manufacturer\'s instructions. The concentration of the DNA was obtained using a ND-1000 spectrophotometer (NanoDrop, Wilmington, DE, USA). To study the germ line, T lymphocytes (CD3+) were isolated using RoboSep according to manufacturer\'s protocol (StemCell Technologies, Vancouver, BC, Canada).

Mutational analysis
-------------------

Mutation screening was performed for genes known to be mutated in myeloid malignancies (*TET2, UTX, CBL, EZH2, ASXL1, TP53, RAS, IDH1/2*, and *DNMT3A*) in the cases for which DNA was available (N = 21). All of the coding exons for *TET2, UTX, EZH2*and *TP53*were screened as previously reported \[[@B13]-[@B17]\] and \[[@B23]\]. Direct genomic sequencing of exons 8 and 9 of *CBL*, exon 12 of *ASXL-1*, exons 1 and 2 of *N-RAS*and *K-RAS*, exon 4 of *IDH-1*and *IDH-2*, and exon 23 of *DNMT3A*was performed as previously described \[[@B15],[@B21],[@B26],[@B27],[@B30]\]. The reference sequence from UCSC Genome Browser was used to identify the position of each amino acid change listed in Table [1](#T1){ref-type="table"} (*TET2*, uc003hxk.2; *EZH2*, uc003wfb.1; *ASXL-1*, uc002wxs.1; *KRAS*, uc001rgp.1; *DNMT-3*, uc002rgc.1). In selected cases CD3+ cells were purified and used as controls to confirm the somatic status of mutations.

###### 

Mutation analysis in the cohort of LEN patients

  Case   Response   *TET2*       *UTX*   *CBL*   *EZH2*   *ASXL1*     *TP53*   *N-RAS*   *K-RAS*   *IDH1*   *IDH2*   *DNMT3A*
  ------ ---------- ------------ ------- ------- -------- ----------- -------- --------- --------- -------- -------- ----------
  1      CR         WT           WT      WT      WT       WT          WT       WT        WT        WT       WT       WT
  2      CR         WT           WT      WT      WT       L775fsX1    WT       WT        WT        WT       WT       WT
  3      PR         WT           WT      WT      WT       WT          WT       WT        WT        WT       WT       WT
  4      NR         WT           WT      WT      WT       WT          WT       WT        WT        WT       WT       WT
  5      CR         WT           WT      WT      WT       E1102D      WT       WT        WT        WT       WT       R882H
  6      PR         P1681fsX2    WT      WT      WT       P1277fsX2   WT       WT        WT        WT       WT       WT
  7      CR         WT           WT      WT      WT       WT          WT       WT        WT        WT       WT       WT
  8      HI         WT           WT      WT      WT       WT          WT       WT        WT        WT       WT       WT
  10     CR         WT           WT      WT      WT       WT          WT       WT        WT        WT       WT       WT
  11     HI         WT           WT      WT      WT       WT          WT       WT        L19F      WT       WT       WT
  12     CR         V1417F       WT      WT      WT       WT          WT       WT        WT        WT       WT       WT
  13     NR         WT           WT      WT      WT       WT          WT       WT        WT        WT       WT       WT
  14     PR         WT           WT      WT      WT       WT          WT       WT        WT        WT       WT       WT
  15     CR         T1978P       WT      WT      WT       WT          WT       WT        WT        WT       WT       WT
  16     NR         WT           WT      WT      WT       S846N       WT       WT        WT        WT       WT       WT
  17     NR         N1068fsX13   WT      WT      WT       WT          WT       WT        WT        WT       WT       WT
  18     NR         WT           WT      WT      WT       WT          WT       WT        WT        WT       WT       WT
  19     NR         P1962L       WT      WT      WT       WT          WT       WT        WT        WT       WT       WT
  20     CR         WT           WT      WT      WT       WT          WT       WT        WT        WT       WT       R882H
  21     HI         WT           WT      WT      T726X    WT          WT       WT        WT        WT       WT       WT
  22     HI         WT           WT      WT      WT       WT          WT       WT        WT        WT       WT       WT

Abbreviation: *CR*complete response; *PR*partial response; *HI*hematologic improvement; *WT*wild type

SNP-A cytogenetics
------------------

Affymetrix Gene Chip Mapping 250 K Assay Kit or Genome-Wide Human SNP Assay Kit 6.0 (Affymetrix, Santa Clara, CA) was used for analysis of 52 and 70 samples with myeloid malignancies, respectively. Following Nsp I digestion (New England Biolabs, Ipswich, MA), fragmented DNA was ligated to adaptor using T4 ligase (New England Biolabs) followed by PCR amplification. The PCR product was hybridized to the array, processed with the Fluidic Station 450 and scanned using the Gene Chip Scanner 3000 (Affymetrix).

Biostatistical evaluation of SNP-A data
---------------------------------------

GeneChip Mapping 250 K Array data, signal intensity and SNP calls were determined using Gene Chip Genotyping Analysis Software Version 4.0 (GTYPE). Copy number and LOH were investigated using Copy Number Analyzer for Affymetrix GeneChip Mapping (CNAG v. 3.0). For Genome-Wide Human SNP Array 6.0, the genotype calls for each individual were determined by the Birdseed version 1 genotype-calling algorithm, embedded in the software included with the Affymetrix Genotyping Console 2.0 (Affymetrix).

For detection of lesions we used the following diagnostic algorithm: lesions identified by SNP-A were compared with the Database of Genomic Variants (<http://projects.tcag.ca/variation/>) and our own internal control series to exclude known copy number variants (CNVs). In our internal control cohort, the largest area of copy neutral loss of heterozygosity (CN-LOH) we observed was 52.5 Mb and the average size of CN-LOH was 7.2 Mb. In addition, we observed that areas of LOH in controls were exclusively interstitial. Consequently, areas of LOH \< 24.8 Mb (mean size ± 2SD) were excluded from analysis in the patient set. Deletions and gains of chromosomal material seen on metaphase karyograms and SNP-A samples that showed a concordantly normal karyotype by both MC and SNP-A testing were not further confirmed. When possible, all other remaining new defects were confirmed using paired analysis of CD3+ cells.

Statistical analysis
--------------------

Demographic and baseline MDS disease characteristics of all patients were summarized descriptively, using medians and ranges. The response differences between 2 groups were compared using Fisher\'s exact test, with a two-sided alpha value of .05 denoting significance.

Results
=======

Comparison between metaphase cytogenetics and other cytogenetic methods
-----------------------------------------------------------------------

We first identified a cohort of 122 patients for whom MC, FISH and SNP-A analyses were performed on the same sample, to evaluate the additional yield of more sensitive techniques for identifying del\[5q\]. In patients with MDS (N = 82), MDS/MPN (N = 13), AML (N = 23), and MPN (N = 4), the detection rate of del\[5q\] increased only marginally with the use of additional techniques, from 24% (MC + FISH), to 25% (MC + SNP-A), 25% (FISH + SNP-A) and 26% (all 3 methods) (Figure [1](#F1){ref-type="fig"}, Table [2](#T2){ref-type="table"}). We also identified 3 cases with copy neutral loss of heterozygosity (CN-LOH) of 5q in this cohort using SNP-A. One region of CN-LOH was found in sAML with complex chromosomal abnormalities including del\[5\]\[q13q33\] by MC, and the other 2 CN-LOH regions were detected in MDS cases with chromosomal abnormalities other than del\[5q\].

###### 

Number and percentage of del\[5q\] detected using metaphase cytogenetics, FISH and SNP-A alone or in combination in myeloid malignancies (N = 122)

               MC    FISH   SNP   MC+FISH   MC+SNP   FISH+SNP   MC+FISH+SNP
  ------------ ----- ------ ----- --------- -------- ---------- -------------
  Number       24    27     25    29        30       31         32
  Percentage   20%   22%    21%   24%       25%      25%        26%

*MC*metaphase cytogenetics; *FISH*fluorescence in situ hybridization; *SNP*single nucleotide polymorphism array-based karyotyping.

Clinical characteristics of non-del\[5q\] patients who had LEN therapy
----------------------------------------------------------------------

Clinical characteristics of the patients with myeloid malignancies without del\[5q\] by MC and who received LEN are summarized in Table [3](#T3){ref-type="table"}; 31 patients received LEN monotherapy (complete response \[CR\], N = 3; partial response \[PR\], N = 2; hematologic improvement \[HI\], N = 9; no response \[NR\], n = 13; not evaluated \[NE\], n = 4), and 11 patients received LEN/azacitidine (AZA) combination therapy (CR, N = 6; PR, N = 1; HI, N = 1; NR, N = 3). Only 1 patient had past history of Hodgkin\'s lymphoma and was suspected to have therapy-related MDS/MPN.

###### 

Summary of clinical characteristics of patients without del\[5q\] on MC who received lenalidomide (N = 42)

  Diagnosis (No. of Patients)                                                 
  ----------------------------------------------------- ---------------- ---- ------------
  MDS                                                                    31   
                                                        RA                    5
                                                        RARS                  13
                                                        RCMD                  1
                                                        RAEB-1                4
                                                        RAEB-2                7
                                                        MDS-U                 1
  MDS/MPN                                                                7    
                                                        CMML-1                2
                                                        CMML-2                2
                                                        MDS/MPN-U             3
  PMF                                                                    2    
  sAML                                                                   2    
                                                                              
  Age (years old)                                                             
                                                                              
                                                        Median (Range)        70 (46-83)
                                                                              
  Sex (No. of Patients)                                                       
                                                                              
                                                        M                     28
                                                        F                     14
                                                                              
  IPSS (No. of Patients)                                                      
                                                                              
                                                        LOW                   12
                                                        INT-1                 11
                                                        INT-2                 7
                                                        HIGH                  1
                                                        not indicated         11
                                                                              
  Duration of MDS (months)                                                    
                                                                              
                                                        Median (Range)        15 (0-118)
                                                                              
  Previous Therapies                                                          
                                                                              
                                                        Yes                   27
                                                        No                    15
                                                                              
  Transfusion dependence (No. of Patients)                                    
                                                                              
                                                        Yes                   30
                                                        No                    12
                                                                              
  Neutropenia (\< 1.5 × 10^9^/μ) (No. of Patients)                            
                                                                              
                                                        Yes                   5
                                                        No                    37
                                                                              
  Thrombocytopenia (\< 100 × 10^9^) (No. of Patients)                         
                                                        Yes                   12
                                                        No                    30
                                                                              
  Therapy (No. of Patients)                                                   
                                                                              
   LEN (5-10 mg/day) alone                                                    30
   LEN high dose (50 mg/day)                                                  1
                                                        LEN/AZA               11
                                                                              
  Duration of LEN therapy (months)                                            
                                                                              
                                                        Median (Range)        5 (0-76)
                                                                              
  Response to therapy (No. of Patients)                                       
                                                                              
                                                        CR                    9
                                                        PR                    3
                                                        HI                    10
                                                        NR                    16
                                                        NE                    4

Abbreviation: *MDS*myelodysplastic syndromes; *RA*refractory anemia; *RARS*refractory anemia with ring sideroblasts; *RCMD*refractory cytopenia with multilineage dysplasia; *RAEB*refractory anemia with excess blasts, *MDS-U*MDS unclassifiable; *MDS/MPN*MDS/myeloproliferative neoplasm; *CMML*chronic myelomonocytic leukemia; *MDS/MPN-U*MDS/MPN unclassifiable; *PMF*primary myelofibrosis; *sAML*secondary acute myeloid leukemia; *M*male; *F*female; *LEN*lenalidomide; *LEN/AZA*LEN/azacitidine; *CR*complete response; *PR*partial response; *HI*hematological improvement; *NR*no response; *NE*not evaluated.

By MC, 32 patients (76%) who received treatment with LEN showed a normal karyotype, 1 patient (2.4%) had no growth to their bone marrow sample, and 9 (21%) had an abnormal karyotype other than del\[5q\] (Table [4](#T4){ref-type="table"}). However, the frequency of an abnormal karyotype was increased to 67% using FISH and SNP-A as karyotyping tools in patients receiving LEN without del\[5q\] by MC (Figure [2](#F2){ref-type="fig"}). Previously cryptic del\[5q\] was detected by both SNP-A and FISH in an additional 1/18 patients with normal MC (Case 19 in Table [4](#T4){ref-type="table"}). Del\[5q\] was also revealed by FISH in 1 patient with unsuccessful MC (Case 14 in Table [4](#T4){ref-type="table"}), but, due to the small size of the clone (8%), SNP-A was not able to detect this lesion.

###### 

Patients characteristics who received LEN without del\[5q\] by MC (N = 42)

  Case   Age (y.o.)   Sex   Diagnosis    IPSS    Therapy           Response   MC                                                                            FISH         SNP-A          
  ------ ------------ ----- ------------ ------- ----------------- ---------- ----------------------------------------------------------------------------- ------------ ------- ------ ---------------
  1      73           M     RAEB-2       INT-2   LEN/AZA           CR         N                                                                             N                    Gain   4q13.2
  2      75           M     RAEB-1       INT-1   LEN/AZA           CR         N                                                                             trisomy 8    9%      Gain   8q11.1q11.21
                                                                                                                                                                                 UPD    11q14.1q21
  3      62           M     MDS/MP N-U   INT-1   LEN/AZA           PR         N                                                                             N                    UPD    1pterp32.3
                                                                                                                                                                                 UPD    3p21.31p21.1
  4      68           M     RAEB-2       HIGH    LEN/AZA           NR         complex karyotype, including trisomy 8, del\[7q\], del\[12\], and del\[20\]   del\[7q\]    68%     Gain   8
                                                                                                                                                            del\[20q\]   60%     Loss   11p14.3p13
                                                                                                                                                            trisomy 8    41%     Loss   12p12.3p11.21
                                                                                                                                                                                 Loss   12q21.1q21.31
                                                                                                                                                                                 Loss   16q22.3q24.3
                                                                                                                                                                                 Loss   1p22.2p22.1
                                                                                                                                                                                 Loss   20q11.2q13.33
                                                                                                                                                                                 Loss   21q11.2q21.1
                                                                                                                                                                                 Loss   2q31.3q32.1
                                                                                                                                                                                 Loss   6q23.3
                                                                                                                                                                                 Gain   7q11.21q11.22
                                                                                                                                                                                 Loss   7q22.1q36.2
  5      68           M     RAEB-2       INT-2   LEN/AZA           CR         47,XY,+8\[[@B6]\]                                                             trisomy 8    9%      Gain   14q11.1q11.2
                                                                                                                                                                                 UPD    19p13.11p12
                                                                                                                                                                                 Gain   8p23.3q24.3
  6      73           M     CMML-1       NE      LEN               PR         N                                                                             del\[20q\]   10%     UPD    9pterp22.2
  7      67           M     PMF          NE      LEN               PR         N                                                                             N                    Loss   11q23.3
  8      66           M     RCMD         LOW     LEN               HI         46,XY,del(20)(q11q13)\[[@B2]\]/4 6,XY\[[@B18]\]                               del\[20q\]   17%     Gain   8q11.1q11.23
  9      69           M     RAEB-1       INT-2   LEN/AZA           CR         N                                                                             N                    NE     
  10     64           M     MDS/MP N-U   NE      LEN               CR         N                                                                             N                    N      
  11     79           F     CMML-2       NE      LEN/AZA           HI         47,XX,+8\[[@B20]\]                                                            trisomy 8    42%     Gain   8
  12     62           F     RAEB-2       INT-2   LEN/AZA           CR         N                                                                             N                    N      
  13     62           F     RARS         INT-1   LEN               NR         46,XX,add(15)(p11.1),add(2 2)(p11.2)\[[@B3]\]/47,idem,+19\[[@B19]\].          del\[7q\]    11%     Gain   19
                                                                                                                                                            del\[7\]     6%      Gain   3q26.1
                                                                                                                                                                                 Gain   4p16.2
  14     72           M     MDS/MPN-U    INT-2   LEN               PR         no growth                                                                     del\[5q\]    8%      Loss   20q11.1q13.12
                                                                                                                                                            del\[20q\]   35%     Loss   2p21p24.1
                                                                                                                                                                                 Loss   8q11.23q12.1
                                                                                                                                                                                 Gain   9p12pter
  15     63           M     RAEB-2       NE      LEN/AZA           CR         N                                                                             N                    Gain   12q24.32
                                                                                                                                                                                 Gain   8q11.1
  16     81           F     RAEB-2       INT-2   LEN/AZA           NR         N                                                                             N                    N      
  17     69           M     CMML-2       \-      LEN/AZA           NR         N                                                                             NE                   Loss   2p22.3
  18     46           M     PMF          \-      LEN               NR         balanced translocation at chromosomes 2 and 22                                NE                   UPD    14q31.3q32.33
                                                                                                                                                                                 Gain   9p24.3p11.1
  19     70           F     sAML         \-      LEN (High dose)   NR         N                                                                             del\[5q\]    33%     Loss   5q31.2
  20     65           F     RARS         LOW     LEN               CR         N                                                                             NE                   N      
  21     70           M     CMML-1       INT-1   LEN               HI         N                                                                             N                    UPD    7q22.1qter
  22     83           M     RARS         LOW     LEN               HI         N                                                                             N                    N      
  23     83           M     RARS         INT-1   LEN               NR         N                                                                             NE                   N      
  24     71           M     MDS-U        INT-1   LEN               NE         N                                                                             NE                   Loss   15q14
  25     69           M     RARS         LOW     LEN               NR         N                                                                             NE                   N      
  26     76           M     RA           INT-1   LEN               NR         N                                                                             NE                   Loss   3p22.3
  27     68           M     RA           INT-1   LEN               NR         N                                                                             NE                   Loss   21q21.2
                                                                                                                                                                                 Gain   3p14.1
                                                                                                                                                                                 Loss   11q14.3
  28     59           M     RARS         LOW     LEN               NR         N                                                                             NE                   N      
  29     73           F     RA           LOW     LEN               NR         N                                                                             NE                   N      
  30     78           F     RARS         LOW     LEN               NE         N                                                                             NE                   UPD    3q21.3qter
  31     78           M     RAEB-1       INT-2   LEN               NR         47,XY,+19                                                                     NE                   Gain   19
  32     80           M     RAEB-1       INT-1   LEN               NE         N                                                                             NE                   Loss   17q11.2
                                                                                                                                                                                 UPD    8p11.2qter
  33     79           F     RARS         INT-1   LEN               HI         N                                                                             NE                   N      
  34     73           F     RARS         LOW     LEN               HI         N                                                                             NE                   Loss   18p11.32
  35     78           F     sAML         \-      LEN               NR         46,XX,t(3;3)                                                                  NE                   Loss   3q26.1
  36     80           M     RAEB-2       INT-2   LEN               NR         N                                                                             NE                   Loss   22q13.2
  37     69           M     RARS         LOW     LEN               HI         N                                                                             NE                   N      
  38     59           F     RA           LOW     LEN               HI         N                                                                             NE                   N      
  39     62           F     RARS         LOW     LEN               NE         N                                                                             NE                   Gain   6p21.32
  40     82           M     RARS         INT-1   LEN               NR         46,XY,del(20)(q11.2)                                                          NE                   Loss   20q11.2q13.2
  41     53           M     RARS         LOW     LEN               HI         N                                                                             NE           N              
  42     56           F     RA           INT-1   LEN               HI         N                                                                             NE                   Loss   9p21.2
                                                                                                                                                                                 Gain   1p21.1

Abbreviation: *M*male; *F*female; *RAEB*refractory anemia with excess blasts; *MDS/MPN-U*myelodysplastic syndromes/myeloproliferative neoplasm, unclassifiable; *CMML*chronic myelomonocytic leukemia; *PMF*primary myelofibrosis; *RCMD*refractory cytopenias with multilineage dysplasia; *RARS*refractory anemia with ring sideroblasts; *sAML*secondary acute myeloid leukemia; *MDS-U*, MDS unclassifiable; *RA*refractory anemia; *LEN*lenalidomide; *AZA*azacitidine; *N*normal; *UPD*uniparental disomy; *NE*not evaluated.

![**Frequency of cytogenetic abnormalities by MC only, or by MC, FISH, and SNP-A**. Compared to MC only (left), addition of FISH and SNP-A (right) improved the detection rate of chromosomal abnormalities dramatically from 21% to 67% in patients receiving LEN without del(5q) by MC (N = 42).](1756-8722-5-4-2){#F2}

Impact of chromosomal abnormalities on response
-----------------------------------------------

In 27 patients who received LEN for more than 2 months, the overall response rate (ORR) was 52%, including 3 CR, 2 PR and 9 HI. Case 19, who was diagnosed as sAML with del\[5q\] by FISH and SNP-A only, was refractory to high-dose LEN. Case 14, a MDS/MPN unclassifiable (MDS/MPN-U) patient in whom a del\[5q\] clone was detected only by FISH due to the small size, had a sustained PR with transfusion independence. The ORR to LEN in patients with normal MC was 60%, vs. 17% for those with chromosomal aberrations by MC (*p*= .08); the addition of FISH or SNP-A did not improve the predictive value of normal cytogenetics (Table [5](#T5){ref-type="table"}). We also analyzed 11 patients without del\[5q\] by MC who received combination therapy with AZA and LEN, for whom the ORR was 73% (6 CR, 1 PR, 1 HI). By MC, 8/11 patients had a normal karyogram and a response of 75%, compared to 3 patients with chromosomal lesions, 1 of whom did not respond. Similar to the results with LEN alone, inclusion of defects detected by SNP-A or FISH did not allow for better separation of responders based on normal cytogenetics by MC. The most frequent cytogenetic abnormality among the patients who received LEN was gain of chromosome 8 material (6/42), followed by the loss of chromosome 20 material (5/42). Patients with gain of chromosome 8 had high ORR to LEN (5 out of 6, 83%) and ORR in patients with chromosome 20 abnormalities was 3 out of 5. The response of patients with all other chromosomal abnormalities by MC, FISH or SNP-A was 44%. These findings indicate that responses tend to be more often observed in patients with gain of chromosome 8 material by either of all 3 karyotyping methods (*p*= .11), although 5 out of those 6 patients received combined LEN/AZA therapy.

###### 

Cytogenetic categories and response to therapy in the cohort of LEN patients

  A. All patient who received LEN for more than 3 months (N = 38)                                                           
  ----------------------------------------------------------------- -------------------------- ---------------------------- ---------
  Categorized by MC only                                            64%                        33%                          0.07
  Categorized by MC/FISH/SNP-A                                      64%                        54%                          0.4
                                                                                                                            
  B. Monotherapy (LEN only) patients (N = 27)                                                                               
                                                                    Normal cytogenetic group   Abnormal cytogenetic group   p value
                                                                                                                            
  Categorized by MC                                                 60%                        17%                          0.08
  only                                                                                                                      
  Categorized by MC/FISH/SNP-A                                      64%                        44%                          0.27
  C. Patients with combination therapy of AZA + LEN (N = 11)                                                                
                                                                                                                            
                                                                    Normal cytogenetic group   Abnormal cytogenetic group   p value
                                                                                                                            
  Categorized by MC only                                            75%                        67%                          0.85
  Categorized by MC/FISH/SNP-A                                      67%                        75%                          0.85

*LEN*lenalidomide; *MC*metaphase cytogenetics; *FISH*fluorescence in situ hybridization; *SNP-A*single nucleotide polymorphism array karyotyping; *AZA*azacitidine.

Impact of mutational status on response
---------------------------------------

In 21 LEN-treated patients (11 patients with LEN only and 10 patients with LEN/AZA), somatic mutations were found in *TET2*(N = 5), *EZH2*(N = 1), *ASXL1*(N = 4), *K-RAS*(N = 1), and *DNMT3A*(N = 2) in 11 patients. *ASXL1*and *DNMT3*, or *TET2*and *ASXL1*mutations were each found in one patient, and each of these patients achieved CR with LEN/AZA or PR with LEN only. ORR was 73% in patients with any of investigated mutations and 70% in patients without a mutation (*p*= .36). For patients treated with LEN only, 3 out of 8 (38%) responders had mutations, and 1 out of 3 (33%) non-responders harbored mutations.

Discussion
==========

Though the mechanism of action of lenalidomide has not been definitively determined, it purportedly works through inhibition of phosphatase activity in the common deleted region (CDR) of 5q that plays a key role in cell cycle regulation, through a defect in ribosomal protein function, via direct cytotoxic mechanisms in patients with the del (5q) cytogenetic abnormality, and supposedly through effects on the bone marrow microenvironment in patients who do not have this lesion, via abrogation of the effects of pro-apoptotic, pro-inflammatory cytokines \[[@B1]-[@B3]\]. Until now, additional markers of responsiveness to LEN beyond del\[5q\] have not been identified.

New cytogenetic tools such as FISH and SNP-A are likely to improve the diagnostic value of cytogenetic diagnostics \[[@B8],[@B9],[@B29]\]. We first assumed that we would detect previously unrecognized cases of del\[5q\] using these techniques. In our cohort of patients given LEN, del\[5q\] cases detected by FISH and/or SNP-A ranged from 2 out of all 42 cases (4.8%) of patients without del\[5q\] by MC, and 1 out of 32 cases (3.1%) with normal MC. These frequencies are similar to those reported in a previous study, in which 5.96% of cases without del\[5q\] by MC and 2.7% of those with normal karyotype by MC were found to be del\[5q\] by FISH \[[@B31]\]. These results suggest that FISH and SNP-A may marginally improve the detection rate of del\[5q\]. While the detection rate of cryptic del\[5q\] was only marginally enhanced with FISH and SNP-A, new karyotyping tools improved the detection rate of other chromosomal abnormalities in our cohort from 21% to 67% compared to MC. A previous study of 43 MDS patients suggested that the cytogenetic pattern correlates with hematologic response; 10 of 12 patients (83%) with del\[5q\] achieved sustained red blood cell transfusion independence, compared with 57% of those with a normal karyotype and 12% of those with other karyotypic abnormalities \[[@B1],[@B32]\]. Consequently, we hypothesized that improved detection of chromosomal abnormalities may better predict poor response to LEN. However, when more abnormalities were found using additional methods, no correlation with response to LEN or LEN/AZA therapy was detected.

We also speculated that we could recognize other chromosomal markers of response or refractoriness to LEN besides del\[5q\] using FISH and SNP-A. For example, trisomy 13 as the sole cytogenetic abnormality was reported to be possible good prognostic factor to LEN therapy \[[@B33]\], but was not detected in our LEN cohort. Instead, we found gain of chromosome 8 material to be predictive of response to LEN, although we acknowledge that 5 out of those 6 patients received combined LEN/AZA therapy \[[@B34],[@B35]\].

In addition to cytogenetic abnormalities, we also studied mutational status of a variety of genes as possible markers of response. For example, *ASXL1*mutations in CMML \[[@B36]\] and *DNMT3A*in AML \[[@B27]\] were reported to be poor prognostic factors. We identified 2 patients with *DNMT3A*mutations in our cohort, both of them achieved CR with LEN or LEN/AZA therapy.

This cohort used in this study has several limitations, including a limited size and the inclusion of patients with heterogenous disease entities. But, we have been able to demonstrate that a normal karyotype and gain of chromosome 8 material was predictive of response to LEN, while additional testing by FISH or SNP-A is not useful for better prediction of response in non-del\[5q\] patients with myeloid malignancies.
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